Rayburn ER - Search Results

1

Chemotherapy and chemosensitization of non-small cell lung cancer with a novel immunomodulatory oligonucleotide targeting Toll-like receptor 9.

Wang H, Rayburn ER, Wang W, Kandimalla ER, Agrawal S, Zhang R. Wang H, et al. Among authors: rayburn er. Mol Cancer Ther. 2006 Jun;5(6):1585-92. doi: 10.1158/1535-7163.MCT-06-0094. Mol Cancer Ther. 2006. PMID: 16818518

2

20(S)-25-methoxyl-dammarane-3beta, 12beta, 20-triol, a novel natural product for prostate cancer therapy: activity in vitro and in vivo and mechanisms of action.

Wang W, Wang H, Rayburn ER, Zhao Y, Hill DL, Zhang R. Wang W, et al. Among authors: rayburn er. Br J Cancer. 2008 Feb 26;98(4):792-802. doi: 10.1038/sj.bjc.6604227. Epub 2008 Feb 5. Br J Cancer. 2008. PMID: 18253123 Free PMC article.

3

Antisense-based cancer therapeutics: are we there yet?

Rayburn ER, Wang H, Zhang R. Rayburn ER, et al. Expert Opin Emerg Drugs. 2006 May;11(2):337-52. doi: 10.1517/14728214.11.2.337. Expert Opin Emerg Drugs. 2006. PMID: 16634705 Review.

4

Experimental therapy of prostate cancer with an immunomodulatory oligonucleotide: effects on tumor growth, apoptosis, proliferation, and potentiation of chemotherapy.

Rayburn ER, Wang W, Zhang Z, Li M, Zhang R, Wang H. Rayburn ER, et al. Prostate. 2006 Nov 1;66(15):1653-63. doi: 10.1002/pros.20485. Prostate. 2006. PMID: 16927305

5

Immunomodulatory oligonucleotides as novel therapy for breast cancer: pharmacokinetics, in vitro and in vivo anticancer activity, and potentiation of antibody therapy.

Wang H, Rayburn ER, Wang W, Kandimalla ER, Agrawal S, Zhang R. Wang H, et al. Among authors: rayburn er. Mol Cancer Ther. 2006 Aug;5(8):2106-14. doi: 10.1158/1535-7163.MCT-06-0158. Mol Cancer Ther. 2006. PMID: 16928832

6

Dexamethasone as a chemosensitizer for breast cancer chemotherapy: potentiation of the antitumor activity of adriamycin, modulation of cytokine expression, and pharmacokinetics.

Wang H, Wang Y, Rayburn ER, Hill DL, Rinehart JJ, Zhang R. Wang H, et al. Among authors: rayburn er. Int J Oncol. 2007 Apr;30(4):947-53. Int J Oncol. 2007. PMID: 17332934

7

Experimental therapy for colon cancer: anti-cancer effects of TLR9 agonism, combination with other therapeutic modalities, and dependence upon p53.

Rayburn ER, Wang W, Zhang R, Wang H. Rayburn ER, et al. Int J Oncol. 2007 Jun;30(6):1511-9. Int J Oncol. 2007. PMID: 17487373

8

Experimental therapy of prostate cancer with novel natural product anti-cancer ginsenosides.

Wang W, Rayburn ER, Hao M, Zhao Y, Hill DL, Zhang R, Wang H. Wang W, et al. Among authors: rayburn er. Prostate. 2008 Jun 1;68(8):809-19. doi: 10.1002/pros.20742. Prostate. 2008. PMID: 18324646

9

Anti-lung cancer effects of novel ginsenoside 25-OCH(3)-PPD.

Wang W, Rayburn ER, Hang J, Zhao Y, Wang H, Zhang R. Wang W, et al. Among authors: rayburn er. Lung Cancer. 2009 Sep;65(3):306-11. doi: 10.1016/j.lungcan.2008.11.016. Epub 2009 Jan 7. Lung Cancer. 2009. PMID: 19131140 Free PMC article.

10

Novel ginsenosides 25-OH-PPD and 25-OCH3-PPD as experimental therapy for pancreatic cancer: anticancer activity and mechanisms of action.

Wang W, Rayburn ER, Zhao Y, Wang H, Zhang R. Wang W, et al. Among authors: rayburn er. Cancer Lett. 2009 Jun 18;278(2):241-248. doi: 10.1016/j.canlet.2009.01.005. Epub 2009 Feb 8. Cancer Lett. 2009. PMID: 19203832 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

42 results

Search Page

Filters